EIF2S1 Antikörper (pSer51)
Kurzübersicht für EIF2S1 Antikörper (pSer51) (ABIN7674371)
Target
Alle EIF2S1 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Bindungsspezifität
- pSer51
-
Verwendungszweck
- Phospho-EIF2S1 antibody antibody
-
Aufreinigung
- Protein A+G purification
-
Reinheit
- ≥95 % as determined by SDS-PAGE
-
Immunogen
-
Immunogen sequence: Peptide
Immunogen: eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa
-
Isotyp
- IgG1
-
-
-
-
Applikationshinweise
- WB: 1:1000-1:10000
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Buffer
- PBS with 0.02 % sodium azide and 50 % glycerol pH 7.3,
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handhabung
- Avoid repeated freeze / thaw cycles.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- -20°C for 12 months (Avoid repeated freeze / thaw cycles.)
-
Haltbarkeit
- 12 months
-
-
- EIF2S1 (Eukaryotic Translation Initiation Factor 2 Subunit 1 (EIF2S1))
-
Andere Bezeichnung
- EIF2S1
-
Hintergrund
-
Synonyms: Eukaryotic translation initiation factor 2 subunit 1|Eukaryotic translation initiation factor 2 subunit alpha (eIF-2-alpha, eIF-2A, eIF-2alpha, eIF2-alpha)|EIF2S1|EIF2A
Background: Functions in the early steps of protein synthesis by forming a ternary complex with GTP and initiator tRNA. This complex binds to a 40S ribosomal subunit, followed by mRNA binding to form a 43S preinitiation complex. Junction of the 60S ribosomal subunit to form the 80S initiation complex is preceded by hydrolysis of the GTP bound to eIF-2 and release of an eIF-2-GDP binary complex. In order for eIF-2 to recycle and catalyze another round of initiation, the GDP bound to eIF-2 must exchange with GTP by way of a reaction catalyzed by eIF-2B.
-
Molekulargewicht
- 36 kDa
-
Gen-ID
- 1965
-
UniProt
- P05198
-
Pathways
- Ribonucleoprotein Complex Subunit Organization, ER-Nucleus Signaling, Hepatitis C
Target
-